It has been suggested that thrombocytopenia occured as the result of phosphorothioate modifications flanking the oligonucleotides to prevent rapid degradation by nucleases, a feature which is avoided with the development of the third generation APOC3 ASO olesarsen which uses Galnac technology for cell internalization and requires lower dosage than volanesorsen (16, 17). The gene discussed is APOC3; the disease is Thrombocytopenia.